Proteomic analysis of MOLT-4 cells treated by valproic acid
Language English Country Netherlands Media print-electronic
Document type Comparative Study, Journal Article, Research Support, Non-U.S. Gov't
- MeSH
- Electrophoresis, Gel, Two-Dimensional MeSH
- Annexin A5 metabolism MeSH
- Apoptosis drug effects MeSH
- Heterogeneous-Nuclear Ribonucleoproteins metabolism MeSH
- Enzyme Inhibitors pharmacology MeSH
- Histone Deacetylase Inhibitors MeSH
- Valproic Acid pharmacology MeSH
- Leukemia, T-Cell drug therapy metabolism pathology MeSH
- Humans MeSH
- Neoplasm Proteins metabolism MeSH
- Proteome analysis MeSH
- Flow Cytometry MeSH
- Signal Transduction MeSH
- Spectrometry, Mass, Matrix-Assisted Laser Desorption-Ionization MeSH
- Cell Survival drug effects MeSH
- Check Tag
- Humans MeSH
- Publication type
- Journal Article MeSH
- Research Support, Non-U.S. Gov't MeSH
- Comparative Study MeSH
- Names of Substances
- Annexin A5 MeSH
- Heterogeneous-Nuclear Ribonucleoproteins MeSH
- Enzyme Inhibitors MeSH
- Histone Deacetylase Inhibitors MeSH
- Valproic Acid MeSH
- Neoplasm Proteins MeSH
- Proteome MeSH
The effect of valproic acid (VA) on protein expression in human T-lymphocytic leukemia cells MOLT-4 was studied. VA is an inhibitor of histonedeacetylases and has a potential use as antitumor agent in leukemia treatment. The authors in this work prove that 4 h long incubation with 2 mmol/l VA causes phosphorylation of histone H2A.X and its colocalization with 53BP1 in nuclear foci. Their co-localization is typical for DSB signaling machinery. These foci were detected in cells after 4 h exposure without increase of Annexin V positive apoptotic cells. Slight increase in apoptosis (Annexin V positivity) after 24 h is accompanied by more intensive increase in phosphorylation of H2A.X and also by formation of nuclear foci containing gammaH2A.X and 53BP1. Treatment of cells with 2 mmol/l VA resulted in induction of apoptosis affecting about 30% of cells after incubation for 72 h. The changes in protein expression were examined after cell incubation with 2 mmol/l VA for 4 h. Proteins were separated by two-dimensional electrophoresis and quantified using image evaluation system. Those exhibiting significant VA-induced abundance alterations were identified by mass spectrometry. Changes in expression of 22 proteins were detected, of which 15 proteins were down-regulated. Proteomic analysis resulted in successful identification of three proteins involving alfa-tubulin 3, tubulin-specific chaperone and heterogeneous nuclear ribonucloprotein F. Expression of seven proteins was up-regulated, including heterogeneous nuclear ribonucloprotein A/B. Identified proteins are related to microtubular system and hnRNP family. Suppression of microtubular proteins and changes of balance among hnRNPs can contribute to proliferation arrest and apoptosis induction.
See more in PubMed
EMBO J. 2001 Dec 17;20(24):6969-78 PubMed
Cancer Res. 2004 Oct 1;64(19):7144-9 PubMed
Ann N Y Acad Sci. 2006 Dec;1091:385-98 PubMed
FEBS Lett. 2001 Jun 22;499(3):199-204 PubMed
Gen Physiol Biophys. 2006 Mar;25(1):65-79 PubMed
Life Sci. 2002 Oct 18;71(22):2633-43 PubMed
Exp Cell Res. 2004 Mar 10;294(1):199-209 PubMed
Expert Opin Investig Drugs. 2004 Jan;13(1):21-38 PubMed
Appl Theor Electrophor. 1988;1(1):35-40 PubMed
Biochim Biophys Acta. 2006 Apr;1765(2):85-100 PubMed
Nature. 2002 May 23;417(6887):455-8 PubMed
DNA Repair (Amst). 2006 May 10;5(5):575-90 PubMed
J Biol Chem. 2005 Jun 17;280(24):22641-50 PubMed
J Biol Chem. 2001 Sep 28;276(39):36734-41 PubMed
Mol Cells. 2001 Aug 31;12(1):1-10 PubMed
J Biol Chem. 2001 Nov 9;276(45):42462-7 PubMed
Cancer Res. 2004 Apr 1;64(7):2390-6 PubMed
J Cell Biol. 2006 Apr 24;173(2):195-206 PubMed
Cancer Res. 2006 Jan 15;66(2):763-9 PubMed
J Proteome Res. 2006 May;5(5):1098-106 PubMed
J Cell Biol. 2000 Dec 25;151(7):1381-90 PubMed
J Cell Sci. 1992 Dec;103 ( Pt 4):953-64 PubMed
Mol Cancer Ther. 2002 Sep;1(11):937-41 PubMed
Cell Growth Differ. 2001 Feb;12(2):61-83 PubMed
Ann Hematol. 2004;83 Suppl 1:S91-2 PubMed
Mol Cancer Ther. 2003 Feb;2(2):151-63 PubMed
